global_document	global_page	document_name	document_number	disease_state
3484766	42	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	4	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	57	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	66	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	47	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	25	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	50	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	32	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	41	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3484766	10	Epcoritamab FAQ (v1.0)	EPCO-AA-00047-FM	DLBCL
3418967	11	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	2	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	6	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	4	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	8	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	12	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	3	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	7	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	5	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	9	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
3418967	1	P_UEGW 2023_RZB-CD SEQUENCE_LB01 (v2.0)	RISN-AA-00453-FM	Crohns Disease (CD)
2686466	46	FutureIBD 2023 Workshop F: Using data to support clinical decision-making in CD  (risa and upa) (v2.0)	RISN-AA-00436-FM	Crohns Disease (CD)
2686466	15	FutureIBD 2023 Workshop F: Using data to support clinical decision-making in CD  (risa and upa) (v2.0)	RISN-AA-00436-FM	Crohns Disease (CD)
2686466	13	FutureIBD 2023 Workshop F: Using data to support clinical decision-making in CD  (risa and upa) (v2.0)	RISN-AA-00436-FM	Crohns Disease (CD)
2686466	9	FutureIBD 2023 Workshop F: Using data to support clinical decision-making in CD  (risa and upa) (v2.0)	RISN-AA-00436-FM	Crohns Disease (CD)
1891919	19	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
1891919	15	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
1891919	33	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
1891919	4	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
1891919	26	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
1891919	44	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
1891919	21	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
1891919	14	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
1891919	27	CLL13 & CLL14 unmutated IGHV; Focus deck (v2.0)	BCL2-AA-00170-FM	Chronic Lymphocytic Leukemia (CLL)
2379863	2	Epcoritamab Dosing Guide (v3.0)	EPCO-AA-00032-FM	DLBCL
2379863	6	Epcoritamab Dosing Guide (v3.0)	EPCO-AA-00032-FM	DLBCL
2379863	4	Epcoritamab Dosing Guide (v3.0)	EPCO-AA-00032-FM	DLBCL
2379863	3	Epcoritamab Dosing Guide (v3.0)	EPCO-AA-00032-FM	DLBCL
2379863	5	Epcoritamab Dosing Guide (v3.0)	EPCO-AA-00032-FM	DLBCL
2379863	1	Epcoritamab Dosing Guide (v3.0)	EPCO-AA-00032-FM	DLBCL
2800057	2	RZB CD Real Life Handling Study - Overview Deck (v1.2)	RISN-AA-00435-FM	Crohns Disease (CD)
2800057	3	RZB CD Real Life Handling Study - Overview Deck (v1.2)	RISN-AA-00435-FM	Crohns Disease (CD)
2800057	14	RZB CD Real Life Handling Study - Overview Deck (v1.2)	RISN-AA-00435-FM	Crohns Disease (CD)
6459680	2	FL Dosing Infographic Vial to Vial Print format (v1.0)	EPCO-AA-00076-FM	Follicular Lymphoma
4289069	1	Epcoritamab DLBCL Syringe to Syringe Reactive iPad/iPhone Format (v2.0)	EPCO-AA-00057-FM	DLBCL
3783359	2	Epcoritamab M22-128 Study Design and Key Eligibility Criteria Infographic (v1.0)	EPCO-AA-00051-FM	DLBCL
3383320	1	RZB CD SEQUENCE Trial Infographic (v2.0)	RISN-AA-00452-FM	Crohns Disease (CD)
522320	20	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	33	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	31	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	4	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	57	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	21	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	24	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	22	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	38	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	34	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
522320	43	Venetoclax and Treatment Sequencing in CLL (v6.0)	BCL2-AA-00013-FM	Chronic Lymphocytic Leukemia (CLL)
4665621	28	Bazinet A, et al. ASCO 2024 & Willekens C, et al. EHA 2024 deck (v3.0)	BCL2-AA-00263-FM	Acute Myeloid Leukemia (AML)
726492	101	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	91	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	55	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	127	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	15	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	114	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	123	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	13	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	130	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	31	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	112	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	22	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	103	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	57	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	48	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	53	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	116	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	107	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	125	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	111	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	102	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	21	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	92	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	119	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	47	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	52	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	115	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	25	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	106	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	7	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	124	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	14	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	113	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	58	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	54	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	90	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	117	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	108	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	45	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	100	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	98	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	1	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	20	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	37	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	46	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	132	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	42	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	40	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	121	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	129	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	17	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	134	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	71	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	80	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	12	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	120	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	38	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	65	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	133	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	16	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	43	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	131	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
726492	122	MURANO Core Deck (v17.0)	BCL2-AA-00037-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	20	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	2	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	19	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	37	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	28	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	33	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	24	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	6	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	31	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	22	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	4	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	17	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	26	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	8	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	30	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	21	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	3	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	29	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	16	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	34	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	25	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	7	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	32	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	23	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	5	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	36	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	27	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	9	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	10	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1014224	18	Prevention of TLS with Venetoclax in CLL (v9.0)	BCL2-AA-00074-FM	Chronic Lymphocytic Leukemia (CLL)
1141698	684	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	99	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	136	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	55	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	37	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	361	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	127	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	46	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	51	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	132	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	42	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	95	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	257	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	158	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	266	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	284	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	686	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	695	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	40	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	138	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	453	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	39	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	48	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	129	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	282	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	53	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	35	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	710	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	305	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	44	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	277	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	137	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	38	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	704	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	128	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	47	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	133	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	304	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	61	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	700	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	106	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	322	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	43	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	124	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	96	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	78	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	708	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	131	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	5	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	41	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	94	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	49	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	135	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	90	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	630	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	36	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	702	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	126	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	45	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	656	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	98	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	11	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	20	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	19	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	15	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	24	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	123	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	6	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	13	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	130	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	705	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	107	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	26	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	125	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	709	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	685	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	12	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	142	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	25	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	7	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	258	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	50	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	14	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	67	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	18	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	711	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	108	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1141698	706	AML Reactive Library_Korea (v1.0)	BCL2-AA-00085-FM	Acute Myeloid Leukemia (AML)
1081211	4	AML VIALE-A, VIALE-C, M14-358 One-Page Summaries (v2.0)	BCL2-AA-00080-FM	Acute Myeloid Leukemia (AML)
1081211	8	AML VIALE-A, VIALE-C, M14-358 One-Page Summaries (v2.0)	BCL2-AA-00080-FM	Acute Myeloid Leukemia (AML)
1081211	3	AML VIALE-A, VIALE-C, M14-358 One-Page Summaries (v2.0)	BCL2-AA-00080-FM	Acute Myeloid Leukemia (AML)
1081211	7	AML VIALE-A, VIALE-C, M14-358 One-Page Summaries (v2.0)	BCL2-AA-00080-FM	Acute Myeloid Leukemia (AML)
1081211	5	AML VIALE-A, VIALE-C, M14-358 One-Page Summaries (v2.0)	BCL2-AA-00080-FM	Acute Myeloid Leukemia (AML)
1081211	9	AML VIALE-A, VIALE-C, M14-358 One-Page Summaries (v2.0)	BCL2-AA-00080-FM	Acute Myeloid Leukemia (AML)
1081211	2	AML VIALE-A, VIALE-C, M14-358 One-Page Summaries (v2.0)	BCL2-AA-00080-FM	Acute Myeloid Leukemia (AML)
1140512	2	Venetoclax Initiation and Dosing Brochure (CLL) (v5.0)	BCL2-AA-00083-FM	Chronic Lymphocytic Leukemia (CLL)
1140512	6	Venetoclax Initiation and Dosing Brochure (CLL) (v5.0)	BCL2-AA-00083-FM	Chronic Lymphocytic Leukemia (CLL)
1140512	4	Venetoclax Initiation and Dosing Brochure (CLL) (v5.0)	BCL2-AA-00083-FM	Chronic Lymphocytic Leukemia (CLL)
1140512	3	Venetoclax Initiation and Dosing Brochure (CLL) (v5.0)	BCL2-AA-00083-FM	Chronic Lymphocytic Leukemia (CLL)
1140512	5	Venetoclax Initiation and Dosing Brochure (CLL) (v5.0)	BCL2-AA-00083-FM	Chronic Lymphocytic Leukemia (CLL)
3290367	2	SEQUENCE initial press release FAQ (v1.0)	RISN-AA-00450-FM	Crohns Disease (CD)
3290367	5	SEQUENCE initial press release FAQ (v1.0)	RISN-AA-00450-FM	Crohns Disease (CD)
4258308	1	M24-287 Clinical Trial Summary Sheet (v1.0)	BCL2-AA-00251-FM	Chronic Lymphocytic Leukemia (CLL)
715049	3	Debulking Strategies with Venetoclax in CLL (v3.0)	BCL2-AA-00035-FM	Chronic Lymphocytic Leukemia (CLL)
3093083	2	Oncology Congress Compendia 2023 (v1.0)	BCMA-BG-00001-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
3093083	63	Oncology Congress Compendia 2023 (v1.0)	BCMA-BG-00001-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
3093083	1	Oncology Congress Compendia 2023 (v1.0)	BCMA-BG-00001-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
3093083	7	Oncology Congress Compendia 2023 (v1.0)	BCMA-BG-00001-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
3093083	230	Oncology Congress Compendia 2023 (v1.0)	BCMA-BG-00001-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
4504346	288	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	4	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	39	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	192	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	305	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	322	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	274	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	126	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	2	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
4504346	3	2024 EHA Congress Compendia (v1.0)	BCMA-AA-00022-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM), Non-Hodgkin's Lymphoma (NHL)
1441583	19	ASH 2021 AML Highlights Deck (v1.0)	BCL2-AA-00126-FM	Acute Myeloid Leukemia (AML)
1441583	22	ASH 2021 AML Highlights Deck (v1.0)	BCL2-AA-00126-FM	Acute Myeloid Leukemia (AML)
1441583	4	ASH 2021 AML Highlights Deck (v1.0)	BCL2-AA-00126-FM	Acute Myeloid Leukemia (AML)
1441583	3	ASH 2021 AML Highlights Deck (v1.0)	BCL2-AA-00126-FM	Acute Myeloid Leukemia (AML)
1441583	18	ASH 2021 AML Highlights Deck (v1.0)	BCL2-AA-00126-FM	Acute Myeloid Leukemia (AML)
1441583	21	ASH 2021 AML Highlights Deck (v1.0)	BCL2-AA-00126-FM	Acute Myeloid Leukemia (AML)
894858	73	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	127	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	44	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	16	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	69	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	20	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	60	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	123	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	31	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	43	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	32	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	102	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	70	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
894858	72	VIALE-A Core Deck (v10.0)	BCL2-AA-00063-FM	Acute Myeloid Leukemia (AML)
1059227	9	Targeting Clonal Evolution (v2.0)	BCL2-AA-00079-FM	Chronic Lymphocytic Leukemia (CLL)
1059227	3	Targeting Clonal Evolution (v2.0)	BCL2-AA-00079-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	11	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	2	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	19	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	6	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	13	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	4	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	17	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	8	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	12	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	3	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	16	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	7	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	14	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	5	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	9	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	10	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
1263527	1	MURANO Safety Data Visualizations (v2.0)	BCL2-AA-00115-FM	Chronic Lymphocytic Leukemia (CLL)
779856	20	Venetoclax SmPC 1L CLL Approval (v1.0)	BCL2-AA-00047-FM	Chronic Lymphocytic Leukemia (CLL)
779856	15	Venetoclax SmPC 1L CLL Approval (v1.0)	BCL2-AA-00047-FM	Chronic Lymphocytic Leukemia (CLL)
779856	17	Venetoclax SmPC 1L CLL Approval (v1.0)	BCL2-AA-00047-FM	Chronic Lymphocytic Leukemia (CLL)
779856	21	Venetoclax SmPC 1L CLL Approval (v1.0)	BCL2-AA-00047-FM	Chronic Lymphocytic Leukemia (CLL)
779856	14	Venetoclax SmPC 1L CLL Approval (v1.0)	BCL2-AA-00047-FM	Chronic Lymphocytic Leukemia (CLL)
4288857	1	Epcoritamab DLBCL Vial to Vial Proactive iPad/iPhone Format (v2.0)	EPCO-AA-00055-FM	DLBCL
3038507	19	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	46	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	15	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	51	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	33	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	24	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	60	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	42	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	59	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	13	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	31	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	22	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	4	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	39	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	48	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	17	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	26	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	62	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	44	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	21	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	29	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	47	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	16	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	34	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	61	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	25	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	7	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	43	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	50	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	14	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	32	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	23	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	58	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	49	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	54	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	18	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	36	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	27	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	45	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	1	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
3038507	30	Venetoclax and Treatment Sequencing in CLL (v9.0)	BCL2-AA-00202-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	11	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	99	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	101	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	20	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	19	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	28	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	15	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	33	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	24	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	6	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	22	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	103	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	40	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	93	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	75	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	48	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	17	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	107	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	26	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	8	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	97	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	88	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	21	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	29	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	16	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	25	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	96	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	14	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	23	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	94	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	49	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	18	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	108	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	27	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	9	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	100	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	98	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	1	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	42	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	13	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	12	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	30	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	102	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	92	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	52	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	43	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	104	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
4647885	41	RWE Deck (v1.0)	BCL2-AA-00262-FM	Chronic Lymphocytic Leukemia (CLL)
1509209	1	M20-356  (ReVenG) Clinical Trial Summary Sheet (v3.0)	BCL2-AA-00128-FM	Chronic Lymphocytic Leukemia (CLL)
3914728	11	Riza CD - SEQUENCE Interactive Infographics (v4.0)	RISN-AA-00463-FM	Crohns Disease (CD)
3914728	19	Riza CD - SEQUENCE Interactive Infographics (v4.0)	RISN-AA-00463-FM	Crohns Disease (CD)
3914728	15	Riza CD - SEQUENCE Interactive Infographics (v4.0)	RISN-AA-00463-FM	Crohns Disease (CD)
3914728	13	Riza CD - SEQUENCE Interactive Infographics (v4.0)	RISN-AA-00463-FM	Crohns Disease (CD)
3914728	17	Riza CD - SEQUENCE Interactive Infographics (v4.0)	RISN-AA-00463-FM	Crohns Disease (CD)
3914728	5	Riza CD - SEQUENCE Interactive Infographics (v4.0)	RISN-AA-00463-FM	Crohns Disease (CD)
3914728	1	Riza CD - SEQUENCE Interactive Infographics (v4.0)	RISN-AA-00463-FM	Crohns Disease (CD)
3231234	11	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	2	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	6	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	4	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	8	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	12	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	21	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	3	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	7	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
3231234	18	Epcoritamab SmPC Deck (v3.0)	EPCO-AA-00044-FM	DLBCL
4783093	11	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	20	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	2	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	55	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	37	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	28	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	46	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	15	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	51	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	33	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	24	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	42	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	6	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	59	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	13	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	31	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	22	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	40	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	57	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	39	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	48	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	17	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	53	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	35	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	26	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	44	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	8	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	12	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	30	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	21	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	3	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	56	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	38	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	29	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	47	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	52	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	16	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	34	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	25	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	43	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	50	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	32	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	23	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	41	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	58	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	49	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	54	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	36	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	27	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	9	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	7	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	14	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4783093	1	VENETIAN (M24-287) STV Deck (v3.0)	BCL2-AA-00268-FM	Chronic Lymphocytic Leukemia (CLL)
4289218	11	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	20	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	19	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	15	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	6	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	13	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	12	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	7	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	14	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	18	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	9	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289218	10	Epcoritamab CDP- Investigator Only (v1.0)	EPCO-AA-00059-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
860424	11	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	20	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	24	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	21	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	25	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	5	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	18	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	12	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	22	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	8	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	23	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	10	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	7	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
860424	9	Venetoclax Dosing and Administration Guide (CLL/AML) (v4.0)	BCL2-AA-00061-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
1059225	3	Clonal Evolution Background (v1.0)	BCL2-AA-00078-FM	Chronic Lymphocytic Leukemia (CLL)
3892927	189	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
3892927	150	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
3892927	152	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
3892927	187	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
3892927	5	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
3892927	157	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
3892927	193	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
3892927	153	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
3892927	188	AML Reactive Library - RWE (RL3) (v3.0)	BCL2-AA-00241-FM	Acute Myeloid Leukemia (AML)
6530721	6	M22-128 Clinical Trial Summary Protocol Version 4 (v1.0)	EPCO-AA-00079-FM	DLBCL
4289001	2	Epcoritamab DLBCL Vial to Vial Proactive Print Format (v2.0)	EPCO-AA-00056-FM	DLBCL
1359994	37	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	15	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	40	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	8	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	3	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	16	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	14	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	18	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	36	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	7	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	4	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1359994	5	VIALE-M Protocol Training Slides (v2.0)	BCL2-AA-00123-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
835800	20	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	55	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	38	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	37	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	40	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	65	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	16	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	5	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	18	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	36	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	60	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	31	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	53	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	62	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	49	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835800	72	VIALE A EHA Oral FAQ (v1.0)	BCL2-AA-00059-FM	Acute Myeloid Leukemia (AML)
835798	4	VIALE A EHA Oral Data Deck (v1.0)	BCL2-AA-00058-FM	Acute Myeloid Leukemia (AML)
835798	5	VIALE A EHA Oral Data Deck (v1.0)	BCL2-AA-00058-FM	Acute Myeloid Leukemia (AML)
835798	19	VIALE A EHA Oral Data Deck (v1.0)	BCL2-AA-00058-FM	Acute Myeloid Leukemia (AML)
835798	15	VIALE A EHA Oral Data Deck (v1.0)	BCL2-AA-00058-FM	Acute Myeloid Leukemia (AML)
835798	6	VIALE A EHA Oral Data Deck (v1.0)	BCL2-AA-00058-FM	Acute Myeloid Leukemia (AML)
835798	18	VIALE A EHA Oral Data Deck (v1.0)	BCL2-AA-00058-FM	Acute Myeloid Leukemia (AML)
5684395	20	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	2	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	19	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	55	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	37	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	28	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	64	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	46	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	33	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	60	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	42	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	59	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	13	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	31	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	40	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	4	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	57	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	39	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	66	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	48	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	35	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	26	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	44	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	12	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	30	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	21	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	65	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	29	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	52	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	34	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	61	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	7	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	43	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	50	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	14	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	32	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	23	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	5	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	41	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	58	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	49	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	54	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	18	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	36	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	63	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	27	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	9	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	45	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
5684395	1	M22-003 MSL STV Deck Protocol Version 2 (v2.0)	EPCO-AA-00064-FM	DLBCL
1753125	3	Managing Potential Drug-Drug Interactions with Venetoclax (Print) (v1.0)	BCL2-AA-00156-FM	Chronic Lymphocytic Leukemia (CLL)
1669666	4	COVID-19 Vaccine Response in CLL - Proactive Communication Deck (v1.0)	BCL2-AA-00149-FM	Chronic Lymphocytic Leukemia (CLL)
1669666	5	COVID-19 Vaccine Response in CLL - Proactive Communication Deck (v1.0)	BCL2-AA-00149-FM	Chronic Lymphocytic Leukemia (CLL)
1242807	29	IL-23 MDT slide deck (v2.0)	RISN-AA-00172-FM	Crohns Disease (CD)
1242807	27	IL-23 MDT slide deck (v2.0)	RISN-AA-00172-FM	Crohns Disease (CD)
4185914	4	Skyrizi Ph3 CD SC Induction (M23-784 - AFFIRM) FAQ (v1.0)	RISN-AA-00467-FM	Crohns Disease (CD)
3941456	2	2024 JSMO Congress Compendia (v1.0)	CMTP-AA-00003-FM	DLBCL, Follicular Lymphoma, Non-small Cell Lung Cancer (NSCLC), Solid Tumor
3941456	50	2024 JSMO Congress Compendia (v1.0)	CMTP-AA-00003-FM	DLBCL, Follicular Lymphoma, Non-small Cell Lung Cancer (NSCLC), Solid Tumor
3941456	1	2024 JSMO Congress Compendia (v1.0)	CMTP-AA-00003-FM	DLBCL, Follicular Lymphoma, Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1851584	20	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	28	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	22	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	4	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	34	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	32	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	23	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	27	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	26	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
1851584	21	Murano del(17p)/TP53mut Focus Deck (v1.0)	BCL2-AA-00166-FM	Chronic Lymphocytic Leukemia (CLL)
4636715	11	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	20	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	15	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	6	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	17	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	26	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	21	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	16	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	14	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	22	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	12	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4636715	19	M19-072 Outpatient Study Story Deck (v1.0)	BCL2-AA-00260-FM	Acute Myeloid Leukemia (AML)
4098335	37	myDataVizTool IMA - Upadacitinib CD (v1.0)	JAKa-AA-00665-FM	Crohns Disease (CD)
4098335	28	myDataVizTool IMA - Upadacitinib CD (v1.0)	JAKa-AA-00665-FM	Crohns Disease (CD)
4098335	46	myDataVizTool IMA - Upadacitinib CD (v1.0)	JAKa-AA-00665-FM	Crohns Disease (CD)
4098335	3	myDataVizTool IMA - Upadacitinib CD (v1.0)	JAKa-AA-00665-FM	Crohns Disease (CD)
4098335	29	myDataVizTool IMA - Upadacitinib CD (v1.0)	JAKa-AA-00665-FM	Crohns Disease (CD)
4636337	11	Venetoclax Therapy Management in AML Core Deck (v1.0)	BCL2-AA-00261-FM	Acute Myeloid Leukemia (AML)
4636337	12	Venetoclax Therapy Management in AML Core Deck (v1.0)	BCL2-AA-00261-FM	Acute Myeloid Leukemia (AML)
4636337	10	Venetoclax Therapy Management in AML Core Deck (v1.0)	BCL2-AA-00261-FM	Acute Myeloid Leukemia (AML)
4636337	24	Venetoclax Therapy Management in AML Core Deck (v1.0)	BCL2-AA-00261-FM	Acute Myeloid Leukemia (AML)
4636337	13	Venetoclax Therapy Management in AML Core Deck (v1.0)	BCL2-AA-00261-FM	Acute Myeloid Leukemia (AML)
4636337	6	Venetoclax Therapy Management in AML Core Deck (v1.0)	BCL2-AA-00261-FM	Acute Myeloid Leukemia (AML)
4636337	34	Venetoclax Therapy Management in AML Core Deck (v1.0)	BCL2-AA-00261-FM	Acute Myeloid Leukemia (AML)
760856	4	Viale-C Data CT.gov (v1.0)	BCL2-AA-00041-FM	Acute Myeloid Leukemia (AML)
760856	5	Viale-C Data CT.gov (v1.0)	BCL2-AA-00041-FM	Acute Myeloid Leukemia (AML)
6137173	361	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
6137173	31	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
6137173	147	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
6137173	314	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
6137173	397	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
6137173	146	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
6137173	32	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
6137173	5	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
6137173	1	2024 ASH Congress Compendia (v2.0)	EPCO-AA-00071-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM)
1430479	20	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	37	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	64	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	51	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	33	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	24	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	13	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	31	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	22	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	4	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	17	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	35	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	44	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	3	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	56	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	16	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	70	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	5	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	10	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	48	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	65	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
1430479	54	Venetoclax MRD/CLL Narrative FAQs (v3.0)	BCL2-AA-00125-FM	Chronic Lymphocytic Leukemia (CLL)
3523924	35	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	43	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	40	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	46	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	51	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	58	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	64	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	60	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	31	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	38	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	76	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
3523924	45	Patient VUE - Interactive Patient Case (v1.0)	BCL2-AA-00232-FM	Acute Myeloid Leukemia (AML)
4148713	1	2024 VASCULITIS WORKSHOP BCN, Immunology Pipeline Table, Medical Booth. (v1.0)	ABBV-AA-00676-FM	Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Giant Cell Arteritis (GCA), Hidradenitis Suppurativa (HS), Juvenile Idiopathic Arthritis (JIA), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Pediatric Psoriasis (Ped Ps), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus, Systemic Sclerosis (SSc), Ulcerative Colitis (UC), Vitiligo
3802384	6	RZB CD Maintenance at 52 weeks Pub Deck (v1.2)	RISN-AA-00462-FM	Crohns Disease (CD)
3802384	4	RZB CD Maintenance at 52 weeks Pub Deck (v1.2)	RISN-AA-00462-FM	Crohns Disease (CD)
3802384	8	RZB CD Maintenance at 52 weeks Pub Deck (v1.2)	RISN-AA-00462-FM	Crohns Disease (CD)
3802384	3	RZB CD Maintenance at 52 weeks Pub Deck (v1.2)	RISN-AA-00462-FM	Crohns Disease (CD)
3802384	16	RZB CD Maintenance at 52 weeks Pub Deck (v1.2)	RISN-AA-00462-FM	Crohns Disease (CD)
3802384	5	RZB CD Maintenance at 52 weeks Pub Deck (v1.2)	RISN-AA-00462-FM	Crohns Disease (CD)
2017019	20	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
2017019	19	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
2017019	31	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
2017019	22	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
2017019	4	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
2017019	21	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
2017019	27	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
2017019	26	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
2017019	34	Murano del(17p)/TP53mut Focus Deck (reactive) (v1.0)	BCL2-AA-00179-FM	Chronic Lymphocytic Leukemia (CLL)
3892923	567	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	262	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	572	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	356	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	518	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	266	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	545	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	569	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	570	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	534	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	372	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	574	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	556	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	565	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	568	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	533	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	573	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	357	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	489	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	5	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	571	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	575	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	566	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	420	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	516	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	371	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	544	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	411	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	263	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	373	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	517	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	364	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	476	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	400	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
3892923	382	AML Reactive Library - IIS & Collaborative Studies (RL2) (v3.0)	BCL2-AA-00240-FM	Acute Myeloid Leukemia (AML)
342038	189	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	495	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	442	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	240	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	509	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	167	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	242	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	196	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	487	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	461	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	241	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	279	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	198	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	253	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	222	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	192	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	480	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	3	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	470	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	250	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	258	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	249	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	5	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	427	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	364	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	252	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	306	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	110	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	200	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	433	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	190	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	109	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	307	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	226	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	208	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	132	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	510	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	194	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	158	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	103	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	507	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	165	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	251	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	431	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	224	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	236	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	506	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	511	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	106	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	195	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	157	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	508	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	432	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	188	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	378	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	28	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	280	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	213	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	105	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	149	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	219	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	107	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	305	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	187	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	268	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	227	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	146	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	304	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	205	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	474	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	203	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	193	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	126	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	494	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
342038	197	AML Reactive Library - AbbVie-Sponsored Trials (RL1) (v15.0)	BCL2-AA-00001-FM	Acute Myeloid Leukemia (AML)
1026914	4	COVID-19 in patients with Hematologic malignancies - Reactive CLL Deck (v5.0)	BCL2-AA-00075-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
1026914	3	COVID-19 in patients with Hematologic malignancies - Reactive CLL Deck (v5.0)	BCL2-AA-00075-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
1026914	5	COVID-19 in patients with Hematologic malignancies - Reactive CLL Deck (v5.0)	BCL2-AA-00075-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
1026914	2	COVID-19 in patients with Hematologic malignancies - Reactive CLL Deck (v5.0)	BCL2-AA-00075-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL)
930731	2	AbbVie R & D Pipeline Overview (v18.0)	APD1-AA-00001-FM	Acute Myeloid Leukemia (AML), Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Chronic Lymphocytic Leukemia (CLL), Crohns Disease (CD), Cystic Fibrosis (CF), Diabetic Retinopathy, Dry Eye Disease (DED), Eyelashes, Giant Cell Arteritis (GCA), Hematologic Malignancies, Hepatitis C Virus (HCV), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-small Cell Lung Cancer (NSCLC), Parkinson's Disease (PD), Prostate Cancer, Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Small Cell Lung Cancer (SCLC), Solid Tumor, Spondyloarthropathy (SpA), Systemic Lupus Erythematosus, Ulcerative Colitis (UC), Vitiligo
2966196	2	Oncology Congress Compendia 2023 (v5.0)	BCMA-AA-00010-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
2966196	63	Oncology Congress Compendia 2023 (v5.0)	BCMA-AA-00010-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
2966196	1	Oncology Congress Compendia 2023 (v5.0)	BCMA-AA-00010-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
2966196	7	Oncology Congress Compendia 2023 (v5.0)	BCMA-AA-00010-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
4720028	20	SEQUENCE Manuscript Infographic PPT (v2.0)	RISN-AA-00471-FM	Crohns Disease (CD)
4720028	13	SEQUENCE Manuscript Infographic PPT (v2.0)	RISN-AA-00471-FM	Crohns Disease (CD)
4720028	8	SEQUENCE Manuscript Infographic PPT (v2.0)	RISN-AA-00471-FM	Crohns Disease (CD)
4720028	7	SEQUENCE Manuscript Infographic PPT (v2.0)	RISN-AA-00471-FM	Crohns Disease (CD)
4720028	1	SEQUENCE Manuscript Infographic PPT (v2.0)	RISN-AA-00471-FM	Crohns Disease (CD)
2379864	2	Epcoritamab Safety Management Card (v3.0)	EPCO-AA-00033-FM	DLBCL
2379864	4	Epcoritamab Safety Management Card (v3.0)	EPCO-AA-00033-FM	DLBCL
2379864	3	Epcoritamab Safety Management Card (v3.0)	EPCO-AA-00033-FM	DLBCL
2379864	1	Epcoritamab Safety Management Card (v3.0)	EPCO-AA-00033-FM	DLBCL
1148810	2	External Field-Medical Reactive Lemzo Deck (v2.0)	BCL2-AA-00089-FM	Acute Myeloid Leukemia (AML), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS)
1930370	189	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	110	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	99	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	101	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	20	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	200	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	91	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	172	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	19	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	136	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	217	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	55	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	118	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	37	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	235	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	73	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	109	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	28	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	226	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	64	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	127	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	244	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	82	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	15	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	213	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	51	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	33	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	114	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	231	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	105	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	222	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	60	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	42	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	240	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	95	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	239	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	68	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	86	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	248	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	13	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	31	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	112	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	22	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	103	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	121	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	93	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	57	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	219	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	138	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	39	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	192	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	75	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	237	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	66	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	228	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	48	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	129	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	84	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	246	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	17	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	116	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	35	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	233	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	71	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	107	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	26	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	224	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	62	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	125	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	206	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	44	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	80	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	79	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	88	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	30	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	102	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	21	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	3	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	120	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	218	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	56	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	92	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	74	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	119	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	65	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	182	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	245	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	47	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	52	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	214	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	151	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	70	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	232	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	34	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	115	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	61	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	223	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	25	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	106	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	241	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	7	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	43	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	124	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	78	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	87	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	212	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	14	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	230	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	32	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	221	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	140	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	41	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	193	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	229	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	67	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	49	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	216	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	18	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	90	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	72	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	234	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	117	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	63	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	225	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	108	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	9	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	81	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	126	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	100	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	98	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	123	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	130	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	220	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	215	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	53	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	242	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	137	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	191	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	38	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	29	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	83	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	128	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	133	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	142	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	96	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	195	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	69	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	50	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	113	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	23	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	104	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	94	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	238	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	247	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	135	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	54	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	153	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	27	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	243	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	10	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	89	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	11	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	24	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	59	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	4	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	134	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	111	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	236	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	227	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	131	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	122	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	139	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	85	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	36	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	132	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
1930370	45	Venetoclax in AML FAQs (v3.0)	BCL2-AA-00172-FM	Acute Myeloid Leukemia (AML)
6459681	1	FL Dosing Infographic Vial to Vial iPad (v2.0)	EPCO-AA-00077-FM	Follicular Lymphoma
2772786	7	Understanding Gastrointestinal Perforations in Patients with IBD (v1.0)	JAKa-AA-00596-FM	Crohns Disease (CD), Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
2772786	9	Understanding Gastrointestinal Perforations in Patients with IBD (v1.0)	JAKa-AA-00596-FM	Crohns Disease (CD), Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC)
835797	20	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	37	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	28	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	24	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	40	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	4	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	53	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	16	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	32	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	5	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	18	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	51	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	33	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	59	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	48	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	12	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	3	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	47	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	6	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	56	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	61	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	49	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
835797	9	VIALE A EHA Abstract FAQ (v1.0)	BCL2-AA-00057-FM	Acute Myeloid Leukemia (AML)
1140674	6	Venetoclax in R/R AML (Reactive) (v2.0)	BCL2-AA-00084-FM	Acute Myeloid Leukemia (AML)
1140674	4	Venetoclax in R/R AML (Reactive) (v2.0)	BCL2-AA-00084-FM	Acute Myeloid Leukemia (AML)
1140674	3	Venetoclax in R/R AML (Reactive) (v2.0)	BCL2-AA-00084-FM	Acute Myeloid Leukemia (AML)
1140674	5	Venetoclax in R/R AML (Reactive) (v2.0)	BCL2-AA-00084-FM	Acute Myeloid Leukemia (AML)
1140674	2	Venetoclax in R/R AML (Reactive) (v2.0)	BCL2-AA-00084-FM	Acute Myeloid Leukemia (AML)
394779	22	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
394779	21	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
394779	18	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
394779	9	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
394779	13	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
394779	39	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
394779	12	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
394779	47	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
394779	14	MURANO FAQ Reactive Deck (v6.0)	BCL2-AA-00007-FM	Chronic Lymphocytic Leukemia (CLL)
4289224	11	Epcoritamab Clinical Development Program (v1.0)	EPCO-AA-00060-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289224	6	Epcoritamab Clinical Development Program (v1.0)	EPCO-AA-00060-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289224	8	Epcoritamab Clinical Development Program (v1.0)	EPCO-AA-00060-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289224	12	Epcoritamab Clinical Development Program (v1.0)	EPCO-AA-00060-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289224	7	Epcoritamab Clinical Development Program (v1.0)	EPCO-AA-00060-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289224	14	Epcoritamab Clinical Development Program (v1.0)	EPCO-AA-00060-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4289224	18	Epcoritamab Clinical Development Program (v1.0)	EPCO-AA-00060-FM	Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma
4281628	1	VIALE-A LTFU Infographic (v1.0)	BCL2-AA-00256-FM	Acute Myeloid Leukemia (AML)
3231150	11	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	20	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	19	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	15	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	33	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	24	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	6	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	13	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	31	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	22	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	4	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	17	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	35	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	26	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	12	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	30	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	21	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	29	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	16	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	34	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	25	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	7	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	5	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	18	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	9	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
3231150	10	Epcoritamab CRS Management Deck (Launch) (v4.0)	EPCO-AA-00042-FM	DLBCL
6066940	17	UPA CD Fistulizing Overview Infographic Deck (v1.0)	JAKa-AA-00713-FM	Crohns Disease (CD)
6066940	3	UPA CD Fistulizing Overview Infographic Deck (v1.0)	JAKa-AA-00713-FM	Crohns Disease (CD)
1817770	24	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	6	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	31	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	4	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	26	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	8	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	32	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	5	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	35	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	19	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	13	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	14	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
1817770	7	Reactive ASCO-EHA 2022 Key Highlights_GMA (v1.0)	EPCO-AA-00023-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL), Non-small Cell Lung Cancer (NSCLC), Solid Tumor
5654047	6	VEN+HMA Genetic Risk Stratification Story Deck (v1.0)	BCL2-AA-00271-FM	Acute Myeloid Leukemia (AML)
5654047	25	VEN+HMA Genetic Risk Stratification Story Deck (v1.0)	BCL2-AA-00271-FM	Acute Myeloid Leukemia (AML)
5654047	10	VEN+HMA Genetic Risk Stratification Story Deck (v1.0)	BCL2-AA-00271-FM	Acute Myeloid Leukemia (AML)
6140695	6	M22-003 Protocol V4 Interactive Trial Summary (v1.0)	EPCO-AA-00072-FM	Follicular Lymphoma
6459676	2	FL Dosing Infographic - Syringe to Syringe Print format (v1.0)	EPCO-AA-00074-FM	Follicular Lymphoma
3776677	20	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	6	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	12	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	14	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	40	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	39	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	1	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	11	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	38	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	27	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	19	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	30	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3776677	49	Venetoclax Therapy Management in AML Core Deck (v3.0)	BCL2-AA-00239-FM	Acute Myeloid Leukemia (AML)
3688927	2	ASH 2023 Congress Compendia (v4.0)	BCMA-AA-00016-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Hematologic Malignancies, Mantle Cell Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL)
3688927	31	ASH 2023 Congress Compendia (v4.0)	BCMA-AA-00016-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Hematologic Malignancies, Mantle Cell Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL)
3688927	1	ASH 2023 Congress Compendia (v4.0)	BCMA-AA-00016-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Hematologic Malignancies, Mantle Cell Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL)
3688927	207	ASH 2023 Congress Compendia (v4.0)	BCMA-AA-00016-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Hematologic Malignancies, Mantle Cell Lymphoma, Multiple Myeloma (MM), Myelodysplastic Syndrome (MDS), Myelofibrosis, Non-Hodgkin's Lymphoma (NHL)
1543815	19	CLL13 Proactive Deck (v11.0)	BCL2-AA-00131-FM	Chronic Lymphocytic Leukemia (CLL)
1543815	15	CLL13 Proactive Deck (v11.0)	BCL2-AA-00131-FM	Chronic Lymphocytic Leukemia (CLL)
1543815	14	CLL13 Proactive Deck (v11.0)	BCL2-AA-00131-FM	Chronic Lymphocytic Leukemia (CLL)
2455704	7	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
2455704	36	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
2455704	37	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
2455704	40	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
2455704	8	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
2455704	16	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
2455704	18	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
2455704	3	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
2455704	5	VIALE-M Protocol Training Slides (v1.0)	BCL2-AA-00187-FM	Acute Myeloid Leukemia (AML), Hematologic Malignancies
1029618	11	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	20	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	2	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	19	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	37	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	15	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	24	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	6	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	13	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	22	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	4	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	39	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	35	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	26	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	12	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	21	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	38	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	16	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	34	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	25	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	7	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	14	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	32	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	23	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	5	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	18	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	36	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	27	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	1	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
1029618	10	AML Disease State & Treatment Landscape (v4.0)	BCL2-AA-00077-FM	Acute Myeloid Leukemia (AML)
6530931	37	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	46	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	33	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	31	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	40	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	48	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	35	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	44	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	30	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	56	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	38	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	47	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	52	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	25	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	7	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	43	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	50	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	32	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	5	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	41	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	67	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	49	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	54	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
6530931	36	M22-128 STV Deck Protocol Version 4 (v1.0)	EPCO-AA-00078-FM	DLBCL
717013	37	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
717013	38	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
717013	61	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
717013	23	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
717013	27	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
717013	4	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
717013	44	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
717013	43	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
717013	67	Neutropenia in Venetoclax CLL Trials (v3.0)	BCL2-AA-00036-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	11	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	19	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	28	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	46	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	15	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	33	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	13	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	40	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	4	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	39	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	48	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	35	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	44	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	30	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	21	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	3	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	38	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	29	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	47	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	16	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	34	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	7	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	43	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	14	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	32	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	5	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	36	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	27	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	9	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	45	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	10	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	37	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	31	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	26	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	8	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
1584944	41	MURANO Core 5 year Update  - Compelling Content (v1.0)	BCL2-AA-00142-FM	Chronic Lymphocytic Leukemia (CLL)
621280	20	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	55	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	37	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	28	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	64	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	15	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	33	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	60	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	31	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	40	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	39	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	48	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	35	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	26	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	44	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	38	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	65	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	29	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	83	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	47	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	34	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	61	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	43	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	69	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	87	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	50	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	14	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	32	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	58	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	76	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	85	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	49	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	54	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	18	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	36	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	45	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	1	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	19	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	73	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	17	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	56	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	72	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
621280	10	CLL-14 Core Study Deck (v20.0)	BCL2-AA-00026-FM	Chronic Lymphocytic Leukemia (CLL)
1194022	3	Managing Potential Drug-Drug Interactions with Venetoclax (Interactive PDF) (v4.0)	BCL2-AA-00093-FM	Chronic Lymphocytic Leukemia (CLL)
1194022	7	Managing Potential Drug-Drug Interactions with Venetoclax (Interactive PDF) (v4.0)	BCL2-AA-00093-FM	Chronic Lymphocytic Leukemia (CLL)
2863222	11	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	15	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	13	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	4	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	12	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	7	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	14	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	18	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	9	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	1	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	10	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
2863222	6	VIALE T poster EBMT 2023 (v2.0)	BCL2-AA-00196-FM	Acute Myeloid Leukemia (AML)
3261922	20	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	55	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	28	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	33	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	42	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	59	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	22	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	57	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	39	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	26	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	62	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	30	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	21	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	3	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	56	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	65	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	29	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	23	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	5	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	41	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	58	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	67	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	54	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	63	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	27	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	11	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	31	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	40	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	66	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	17	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	44	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	12	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	38	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	52	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	69	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	32	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	18	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	36	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	10	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	51	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	34	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	50	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	37	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	48	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	8	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
3261922	47	VIALE T v7 protocol deck for external use with VIALE T sites only (v2.0)	BCL2-AA-00221-FM	Acute Myeloid Leukemia (AML)
860425	37	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	33	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	68	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	84	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	47	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	19	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	46	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	13	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	29	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	25	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	55	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	24	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	59	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	57	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	17	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	56	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	61	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	27	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	62	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	8	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	54	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	40	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	38	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	7	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	43	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	23	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
860425	49	Pan Ven Cross-indication Scientific Story (v1.0)	BCL2-AA-00062-FM	Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myeloid Leukemia (CML), Hematologic Malignancies, Multiple Myeloma (MM)
3602194	8	RINVOQ IBD Malignancies deck - SAFETY SERIES (v1.0)	JAKa-AA-00646-FM	Crohns Disease (CD), Ulcerative Colitis (UC)
3602194	18	RINVOQ IBD Malignancies deck - SAFETY SERIES (v1.0)	JAKa-AA-00646-FM	Crohns Disease (CD), Ulcerative Colitis (UC)
703483	22	MRD in patients with CLL (v3.0)	BCL2-AA-00034-FM	Chronic Lymphocytic Leukemia (CLL)
703483	30	MRD in patients with CLL (v3.0)	BCL2-AA-00034-FM	Chronic Lymphocytic Leukemia (CLL)
703483	21	MRD in patients with CLL (v3.0)	BCL2-AA-00034-FM	Chronic Lymphocytic Leukemia (CLL)
703483	5	MRD in patients with CLL (v3.0)	BCL2-AA-00034-FM	Chronic Lymphocytic Leukemia (CLL)
703483	9	MRD in patients with CLL (v3.0)	BCL2-AA-00034-FM	Chronic Lymphocytic Leukemia (CLL)
703483	6	MRD in patients with CLL (v3.0)	BCL2-AA-00034-FM	Chronic Lymphocytic Leukemia (CLL)
6019531	33	EPCORE NHL-1 DLBCL Infographic Deck (v1.0)	EPCO-AA-00068-FM	DLBCL
6019531	6	EPCORE NHL-1 DLBCL Infographic Deck (v1.0)	EPCO-AA-00068-FM	DLBCL
6019531	53	EPCORE NHL-1 DLBCL Infographic Deck (v1.0)	EPCO-AA-00068-FM	DLBCL
6019531	52	EPCORE NHL-1 DLBCL Infographic Deck (v1.0)	EPCO-AA-00068-FM	DLBCL
6019531	7	EPCORE NHL-1 DLBCL Infographic Deck (v1.0)	EPCO-AA-00068-FM	DLBCL
2937776	11	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	2	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	28	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	4	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	3	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	25	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	5	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	27	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	9	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
2937776	10	Manuscript Overview Deck: UPA as Induction & Maintenance Therapy for CD (v1.0)	JAKa-AA-00606-FM	Crohns Disease (CD)
1939676	11	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	110	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	99	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	101	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	20	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	2	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	91	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	19	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	55	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	37	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	73	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	28	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	64	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	82	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	15	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	51	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	33	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	24	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	105	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	60	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	42	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	6	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	59	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	77	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	68	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	13	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	31	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	112	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	22	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	40	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	4	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	93	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	39	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	75	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	48	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	84	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	17	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	35	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	71	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	107	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	26	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	62	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	44	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	97	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	111	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	30	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	21	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	3	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	56	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	92	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	74	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	38	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	65	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	29	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	52	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	16	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	70	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	34	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	115	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	25	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	106	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	7	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	43	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	96	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	78	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	69	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	87	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	50	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	14	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	23	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	58	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	67	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	85	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	18	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	90	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	72	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	63	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	108	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	9	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	81	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1939676	89	Risankizumab CD - Global IMA (v4.0)	RISN-AA-00395-FM	Crohns Disease (CD)
1087234	19	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	15	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	33	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	24	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	42	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	40	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	4	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	17	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	35	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	8	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	21	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	3	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	47	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	25	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	43	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	32	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	49	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	27	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	5	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
1087234	9	Venetoclax Regimens in Patients with High Risk CLL (v3.0)	BCL2-AA-00082-FM	Chronic Lymphocytic Leukemia (CLL)
4289145	2	Epcoritamab DLBCL Syringe to Syringe Reactive Print Format (v2.0)	EPCO-AA-00058-FM	DLBCL
4289145	1	Epcoritamab DLBCL Syringe to Syringe Reactive Print Format (v2.0)	EPCO-AA-00058-FM	DLBCL
2277645	11	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	110	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	99	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	101	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	91	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	55	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	118	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	28	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	145	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	64	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	82	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	15	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	51	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	13	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	112	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	75	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	84	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	17	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	62	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	80	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	8	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	12	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	3	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	120	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	92	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	119	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	83	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	47	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	115	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	78	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	139	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	94	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	76	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	54	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	117	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	81	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	126	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	98	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	10	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
2277645	89	Upadacitinib CD - Global IMA (v3.0)	JAKa-AA-00573-FM	Crohns Disease (CD)
4303797	8	Crushed and Ground Venetoclax Tablets poster presentation (v1.0)	BCL2-AA-00257-FM	Acute Myeloid Leukemia (AML)
4303797	14	Crushed and Ground Venetoclax Tablets poster presentation (v1.0)	BCL2-AA-00257-FM	Acute Myeloid Leukemia (AML)
4303797	5	Crushed and Ground Venetoclax Tablets poster presentation (v1.0)	BCL2-AA-00257-FM	Acute Myeloid Leukemia (AML)
4303797	9	Crushed and Ground Venetoclax Tablets poster presentation (v1.0)	BCL2-AA-00257-FM	Acute Myeloid Leukemia (AML)
4303797	1	Crushed and Ground Venetoclax Tablets poster presentation (v1.0)	BCL2-AA-00257-FM	Acute Myeloid Leukemia (AML)
4303797	10	Crushed and Ground Venetoclax Tablets poster presentation (v1.0)	BCL2-AA-00257-FM	Acute Myeloid Leukemia (AML)
3231035	11	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	20	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	13	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	4	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	17	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	12	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	16	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	7	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	5	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	9	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
3231035	10	Epcoritamab ICANS Management Deck (Launch) (v5.0)	EPCO-AA-00041-FM	DLBCL
1208132	4	Practical Considerations for Developing a Venetoclax Initiation Protocol (Print/Electronic format) (v3.0)	BCL2-AA-00106-FM	Chronic Lymphocytic Leukemia (CLL)
1208132	8	Practical Considerations for Developing a Venetoclax Initiation Protocol (Print/Electronic format) (v3.0)	BCL2-AA-00106-FM	Chronic Lymphocytic Leukemia (CLL)
1208132	3	Practical Considerations for Developing a Venetoclax Initiation Protocol (Print/Electronic format) (v3.0)	BCL2-AA-00106-FM	Chronic Lymphocytic Leukemia (CLL)
1208132	5	Practical Considerations for Developing a Venetoclax Initiation Protocol (Print/Electronic format) (v3.0)	BCL2-AA-00106-FM	Chronic Lymphocytic Leukemia (CLL)
3057891	11	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	20	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	6	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	26	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	8	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	21	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	23	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	5	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	18	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	4	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
3057891	7	MSL Reactive Slide Deck- AML, CLL, MM AND NSCLC (v1.0)	cMET-AA-00028-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-small Cell Lung Cancer (NSCLC)
1794057	22	EHA ASCO 2022 AML Highlights (v1.0)	BCL2-AA-00159-FM	Acute Myeloid Leukemia (AML)
1794057	26	EHA ASCO 2022 AML Highlights (v1.0)	BCL2-AA-00159-FM	Acute Myeloid Leukemia (AML)
1794057	3	EHA ASCO 2022 AML Highlights (v1.0)	BCL2-AA-00159-FM	Acute Myeloid Leukemia (AML)
1794057	20	EHA ASCO 2022 AML Highlights (v1.0)	BCL2-AA-00159-FM	Acute Myeloid Leukemia (AML)
1794057	40	EHA ASCO 2022 AML Highlights (v1.0)	BCL2-AA-00159-FM	Acute Myeloid Leukemia (AML)
1794057	4	EHA ASCO 2022 AML Highlights (v1.0)	BCL2-AA-00159-FM	Acute Myeloid Leukemia (AML)
1794057	44	EHA ASCO 2022 AML Highlights (v1.0)	BCL2-AA-00159-FM	Acute Myeloid Leukemia (AML)
1794057	23	EHA ASCO 2022 AML Highlights (v1.0)	BCL2-AA-00159-FM	Acute Myeloid Leukemia (AML)
3249915	11	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	20	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	2	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	19	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	37	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	28	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	46	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	15	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	33	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	24	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	42	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	6	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	13	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	31	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	22	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	40	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	39	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	17	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	35	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	26	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	44	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	8	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	12	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	30	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	21	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	38	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	29	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	47	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	16	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	34	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	25	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	7	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	43	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	14	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	32	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	23	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	41	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	18	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	36	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	27	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	9	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	45	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	1	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
3249915	10	REVENG (M20-356) STV Deck 2024 (v3.0)	BCL2-AA-00220-FM	Chronic Lymphocytic Leukemia (CLL)
4149272	110	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	99	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	101	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	91	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	118	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	73	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	109	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	82	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	114	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	105	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	60	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	123	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	95	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	77	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	86	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	130	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	103	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	121	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	93	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	75	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	66	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	84	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	80	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	97	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	79	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	88	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	111	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	120	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	74	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	65	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	83	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	47	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	133	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	70	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	115	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	106	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	69	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	87	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	104	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	122	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	94	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	76	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	67	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	72	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	117	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	108	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	81	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	100	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
4149272	98	FL Interactive Tool (v2.0)	EPCO-AA-00053-FM	Follicular Lymphoma
1851581	20	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	19	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	33	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	24	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	22	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	4	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	26	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	21	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	25	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	23	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	31	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	27	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1851581	10	Murano IGHV unmutated Focus Deck (v1.0)	BCL2-AA-00165-FM	Chronic Lymphocytic Leukemia (CLL)
1500313	15	CLL13 Reactive Core Deck (v14.0)	BCL2-AA-00127-FM	Chronic Lymphocytic Leukemia (CLL)
1500313	8	CLL13 Reactive Core Deck (v14.0)	BCL2-AA-00127-FM	Chronic Lymphocytic Leukemia (CLL)
1500313	3	CLL13 Reactive Core Deck (v14.0)	BCL2-AA-00127-FM	Chronic Lymphocytic Leukemia (CLL)
1500313	34	CLL13 Reactive Core Deck (v14.0)	BCL2-AA-00127-FM	Chronic Lymphocytic Leukemia (CLL)
1500313	27	CLL13 Reactive Core Deck (v14.0)	BCL2-AA-00127-FM	Chronic Lymphocytic Leukemia (CLL)
546842	24	Venetoclax Therapy Management in AML Core Deck (v8.0)	BCL2-AA-00016-FM	Acute Myeloid Leukemia (AML)
546842	13	Venetoclax Therapy Management in AML Core Deck (v8.0)	BCL2-AA-00016-FM	Acute Myeloid Leukemia (AML)
546842	12	Venetoclax Therapy Management in AML Core Deck (v8.0)	BCL2-AA-00016-FM	Acute Myeloid Leukemia (AML)
546842	6	Venetoclax Therapy Management in AML Core Deck (v8.0)	BCL2-AA-00016-FM	Acute Myeloid Leukemia (AML)
546842	41	Venetoclax Therapy Management in AML Core Deck (v8.0)	BCL2-AA-00016-FM	Acute Myeloid Leukemia (AML)
546842	10	Venetoclax Therapy Management in AML Core Deck (v8.0)	BCL2-AA-00016-FM	Acute Myeloid Leukemia (AML)
1317584	13	GLOW Study Core Deck (v3.0)	BCL2-AA-00119-FM	Chronic Lymphocytic Leukemia (CLL)
1317584	12	GLOW Study Core Deck (v3.0)	BCL2-AA-00119-FM	Chronic Lymphocytic Leukemia (CLL)
1317584	3	GLOW Study Core Deck (v3.0)	BCL2-AA-00119-FM	Chronic Lymphocytic Leukemia (CLL)
1317584	1	GLOW Study Core Deck (v3.0)	BCL2-AA-00119-FM	Chronic Lymphocytic Leukemia (CLL)
1317584	6	GLOW Study Core Deck (v3.0)	BCL2-AA-00119-FM	Chronic Lymphocytic Leukemia (CLL)
1317584	4	GLOW Study Core Deck (v3.0)	BCL2-AA-00119-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	11	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	37	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	73	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	15	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	31	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	22	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	40	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	39	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	75	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	35	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	12	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	30	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	74	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	38	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	25	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	69	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	14	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	41	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	76	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	18	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	36	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	10	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	20	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	19	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	33	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	24	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	13	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	4	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	21	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4232369	34	IGHV Focus Deck (CLL14) (v4.0)	BCL2-AA-00245-FM	Chronic Lymphocytic Leukemia (CLL)
4189403	20	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	19	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	28	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	15	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	33	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	24	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	6	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	31	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	22	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	4	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	17	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	35	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	26	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	8	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	12	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	21	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	3	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	34	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	14	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	32	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	23	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	5	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	18	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	36	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	27	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
4189403	10	Global P_Future of Immunology (v1.0)	ABBV-AA-00679-FM	Adolescent Hidradenitis Suppurativa (HS), Alopecia Areata, Ankylosing Spondylitis (AS), Atopic Dermatitis (AD), Crohns Disease (CD), Hidradenitis Suppurativa (HS), Immunology Cross-TA, Inflammatory Bowel Disease (IBD), Non-radiographic Axial Spondyloarthropathy (nrAxSpA), Psoriasis (Ps), Psoriatic Arthritis (PsA), Rheumatoid Arthritis (RA), Ulcerative Colitis (UC)
1542494	11	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	19	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	55	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	37	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	28	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	64	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	46	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	51	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	33	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	24	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	60	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	42	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	13	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	31	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	22	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	40	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	4	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	57	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	39	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	66	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	48	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	35	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	62	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	8	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	12	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	30	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	21	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	56	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	29	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	52	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	34	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	50	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	14	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	32	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	23	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	41	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	58	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	18	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	27	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	1	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	44	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	38	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	65	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	47	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	16	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	9	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	15	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	49	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	45	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1542494	61	VIALE-T (M19-063) Protocol Overview (v3.0)	BCL2-AA-00130-FM	Acute Myeloid Leukemia (AML)
1753607	3	AbbVie Venetoclax Production Critical Steps_Presentation (v1.0)	BCL2-AA-00157-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Hematologic Malignancies
1753607	7	AbbVie Venetoclax Production Critical Steps_Presentation (v1.0)	BCL2-AA-00157-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Hematologic Malignancies
1753607	5	AbbVie Venetoclax Production Critical Steps_Presentation (v1.0)	BCL2-AA-00157-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Hematologic Malignancies
1753607	9	AbbVie Venetoclax Production Critical Steps_Presentation (v1.0)	BCL2-AA-00157-FM	Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Hematologic Malignancies
5892553	99	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	101	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	91	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	253	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	334	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	370	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	136	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	352	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	262	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	181	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	109	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	226	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	127	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	82	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	330	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	15	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	51	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	132	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	114	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	150	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	60	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	123	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	338	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	95	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	293	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	59	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	356	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	194	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	77	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	239	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	347	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	86	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	130	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	103	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	93	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	273	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	192	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	75	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	156	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	345	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	129	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	363	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	84	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	170	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	332	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	134	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	350	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	107	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	341	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	143	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	62	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	125	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	358	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	79	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	88	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	111	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	21	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	199	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	371	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	92	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	344	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	128	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	133	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	61	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	106	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	160	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	339	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	78	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	87	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	131	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	122	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	139	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	94	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	76	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	157	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	355	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	184	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	85	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	135	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	72	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	63	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	261	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	324	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	81	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	126	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	100	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5892553	98	Epcoritamab Comprehensive Reactive Deck (v1.0)	EPCO-AA-00066-FM	DLBCL
5958082	11	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	6	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	13	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	4	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	17	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	12	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	7	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	14	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	5	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
5958082	9	AMPLIFY ASH 2024 Reactive Deck (v3.0)	BCL2-AA-00275-FM	Chronic Lymphocytic Leukemia (CLL)
6292002	55	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	37	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	28	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	64	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	46	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	15	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	51	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	33	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	60	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	42	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	59	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	31	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	66	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	53	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	35	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	26	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	62	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	44	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	38	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	29	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	47	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	34	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	25	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	43	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	50	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	32	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	23	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	41	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	58	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	49	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	36	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	27	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
6292002	45	M22-003 STV Deck Protocol V4 (v1.0)	EPCO-AA-00073-FM	Follicular Lymphoma
835795	11	VIALE A EHA Abstract Data Deck (v1.0)	BCL2-AA-00056-FM	Acute Myeloid Leukemia (AML)
835795	4	VIALE A EHA Abstract Data Deck (v1.0)	BCL2-AA-00056-FM	Acute Myeloid Leukemia (AML)
835795	5	VIALE A EHA Abstract Data Deck (v1.0)	BCL2-AA-00056-FM	Acute Myeloid Leukemia (AML)
835795	6	VIALE A EHA Abstract Data Deck (v1.0)	BCL2-AA-00056-FM	Acute Myeloid Leukemia (AML)
835795	12	VIALE A EHA Abstract Data Deck (v1.0)	BCL2-AA-00056-FM	Acute Myeloid Leukemia (AML)
5223216	20	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	19	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	28	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	6	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	4	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	26	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	30	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	3	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	7	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	32	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	5	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
5223216	49	NHL Bispecific Journal Club (v2.0)	EPCO-AA-00063-FM	DLBCL, Follicular Lymphoma
3676555	4	2023_ASH EPCOR FAQs (v1.0)	EPCO-AA-00050-FM	DLBCL
3676555	12	2023_ASH EPCOR FAQs (v1.0)	EPCO-AA-00050-FM	DLBCL
3676555	7	2023_ASH EPCOR FAQs (v1.0)	EPCO-AA-00050-FM	DLBCL
3676555	1	2023_ASH EPCOR FAQs (v1.0)	EPCO-AA-00050-FM	DLBCL
3231192	2	Epcoritamab Dosing Guide Poster (v4.0)	EPCO-AA-00043-FM	DLBCL
3231192	1	Epcoritamab Dosing Guide Poster (v4.0)	EPCO-AA-00043-FM	DLBCL
3649708	2	Epcoritamab M20-621 Study Design and Key Eligibility Criteria Infographic (v1.0)	EPCO-AA-00049-FM	DLBCL
3649708	4	Epcoritamab M20-621 Study Design and Key Eligibility Criteria Infographic (v1.0)	EPCO-AA-00049-FM	DLBCL
788167	6	VIALE A Press Release FAQ (v2.0)	BCL2-AA-00049-FM	Acute Myeloid Leukemia (AML)
788167	8	VIALE A Press Release FAQ (v2.0)	BCL2-AA-00049-FM	Acute Myeloid Leukemia (AML)
788167	21	VIALE A Press Release FAQ (v2.0)	BCL2-AA-00049-FM	Acute Myeloid Leukemia (AML)
788167	10	VIALE A Press Release FAQ (v2.0)	BCL2-AA-00049-FM	Acute Myeloid Leukemia (AML)
788167	22	VIALE A Press Release FAQ (v2.0)	BCL2-AA-00049-FM	Acute Myeloid Leukemia (AML)
788167	7	VIALE A Press Release FAQ (v2.0)	BCL2-AA-00049-FM	Acute Myeloid Leukemia (AML)
788167	13	VIALE A Press Release FAQ (v2.0)	BCL2-AA-00049-FM	Acute Myeloid Leukemia (AML)
4441341	4	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
4441341	129	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
4441341	84	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
4441341	18	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
4441341	36	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
4441341	144	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
4441341	1	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
4441341	2	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
4441341	3	ASCO 2024 Hematology Compendium (v1.0)	EPCO-AA-00061-FM	Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), DLBCL, Follicular Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma (MM)
